BCRX Relative Valuation
BCRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCRX is overvalued; if below, it's undervalued.
Historical Valuation
BioCryst Pharmaceuticals Inc (BCRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.64 is considered Undervalued compared with the five-year average of -35.05. The fair price of BioCryst Pharmaceuticals Inc (BCRX) is between 11.58 to 43.90 according to relative valuation methord. Compared to the current price of 10.37 USD , BioCryst Pharmaceuticals Inc is Undervalued By 10.43%.
Relative Value
Fair Zone
11.58-43.90
Current Price：10.37
10.43%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-5.14
P/B
Median3y
-4.86
Median5y
-9.84
-1.16
FCF Yield
Median3y
-7.11
Median5y
-7.62
Competitors Valuation Multiple
The average P/S ratio for BCRX's competitors is 21.08, providing a benchmark for relative valuation. BioCryst Pharmaceuticals Inc Corp (BCRX) exhibits a P/S ratio of 3.64, which is -82.75% above the industry average. Given its robust revenue growth of 56.89%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is BioCryst Pharmaceuticals Inc (BCRX) currently overvalued or undervalued?
What is BioCryst Pharmaceuticals Inc (BCRX) fair value?
How does BCRX's valuation metrics compare to the industry average?
What is the current P/B ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jun 16 2025?
What is the current FCF Yield for BioCryst Pharmaceuticals Inc (BCRX) as of Jun 16 2025?
What is the current Forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX) as of Jun 16 2025?